Experts Unravel the Top 5 Myths Related to Bioequivalence
生物学的同等性は、薬物動態を用いて経口医薬品製剤の安全性と効果を橋渡しする役割を果たします。The concepts…
Certara2022年2月18日
The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics
We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…
Certara2022年2月7日
Improved Workflow and Expanded functionality of RsNLME v1.1
R Speaks NLME (RsNLME) is a collection of R packages and companion RShiny apps that…
Certara2022年1月31日
Choosing an eCTD Submissions Vendor: Your Complete Checklist
Selecting the right electronic submission services vendor for your organization’s regulatory submissions to health authorities…
Certara2022年1月28日
Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development
This blog will reflect on 3 things drug developers should pay attention to regarding safety…
Certara2022年1月24日
Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies
Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…
Certara2022年1月19日
R Speaks NLME (RsNLME) Overview
This recording shows an overall review of RsNLME using Pirana and an extensive explanation on…
Certara2022年1月19日
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
歴史的に、がん治療薬の投与戦略は最大耐容量に焦点が当てられてきました。This…
Certara2022年1月13日
PBPK Modeling of Antibody-Drug Conjugates – Concept and Application
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…
Certara2022年1月13日
